Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Addition of pimecrolimus cream 1% to a topical corticosteroid treatment regimen in paediatric patients with severe atopic dermatitis: A randomized, double-blind trial
Journal of Dermatological Treatment, Volume 21, No. 3, Year 2010
Notification
URL copied to clipboard!
Description
Background: Pimecrolimus and topical corticosteroids (TCS) combination therapy may provide an alternative treatment for patients with severe atopic dermatitis (AD), with faster clearance of disease flares, consequently reducing the duration of TCS treatment.Objective: To assess the safety profile of pimecrolimus cream 1% combined with fluticasone versus fluticasone alone in paediatric patients with severe AD.Methods: Patients (n 376) were randomized to a combination of pimecrolimus cream 1% with fluticasone or vehicle plus fluticasone for 4 weeks. The primary outcome measure was the frequency of clinically relevant pre-defined adverse events (AEs) associated with the topical use of corticosteroids in patients with severe AD.Results: Erythematous rash was the only AE, occurring more frequently in the combination group, while there were no noticeable differences in the frequency of other AEs of clinical interest between treatment groups. Efficacy variables were comparable between the two groups. A trend for greater time to relapse was observed for the combination of pimecrolimus cream 1% with fluticasone in patients who were clear at the end of treatment, with a marked improvement in facial AD.Conclusion: In paediatric patients with severe AD the overall safety profile of pimecrolimus cream 1% combined with fluticasone was similar to that of fluticasone alone. © 2010 Informa UK Ltd.
Authors & Co-Authors
Meurer, Michael
Germany, Dresden
Universitätsklinikum Carl Gustav Carus Dresden
Eichenfield, Lawrence F.
United States, La Jolla
University of California, San Diego
Ho., Vincent C.Y.
Canada, Vancouver
The University of British Columbia
Potter, Paul C.
South Africa, Cape Town
University of Cape Town Lung Institute
Werfel, Thomas T.
Germany, Hannover
Hannover Medical School
Hultsch, Thomas
Switzerland, Basel
Novartis International ag
Statistics
Citations: 22
Authors: 6
Affiliations: 6
Identifiers
Doi:
10.3109/09546630903410158
ISSN:
09546634
e-ISSN:
14711753
Research Areas
Disability